Skip to main content

Branded

  • FDA approves Janssen’s plaque psoriasis drug Tremfya

    SILVER SPRING, Md. — The Food and Drug Adminisration has approved Janssen Biotech’s new treatment for plaque psoriasis, the company announced Thursday. Tremfya (guselkumab) is the first drug to be approved that selectively blocks a key plaque psoriasis cytokine, the company said.

  • PhRMA adds 2 VPs
    WASHINGTON — The Pharmaceutical Research and Manufacturers of America this week announced two new additions to its ranks. The company has added Mike Hotra as VP of its public affairs team, and Ken McKay as VP state government affairs. 
     

  • FDA approves first new sickle cell drug in almost 20 years

    SILVER SPRING, Md. — The Food and Drug Administration on Friday approved a new treatment for severe complications from sickle cell disease — the first in nearly 20 years for the blood disorder. Endari (L-glutamine oral powder) was developed and is manufactured by Emmaus Life Sciences

  • Senators urge Mattis to implement TRICARE pharmacy pilot

    WASHINGTON — Twenty-one senators recently sent a letter to Defense Sec. James Mattis, encouraging him to implement the TRICARE Acqisition Cost Parity Pilot Program for Retail Pharmacy.

  • Endo to divest Mexican generics arm Grupo Farmcéutico SOMAR

    DUBLIN — Endo will be selling its Mexico City-based Grupo Farmcéuitco SOMAR division to Advent International, the company announced Wednesday. The deal will see the Mexican private generics leader sold to Advent for roughly $124 million.

  • FDA approves new indication for Amgen’s Vectibix

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Amgen’s Vectibix (panitumumab). The biologic has been approved to treat patients with wild-type RAS metastatic colorectal cancer, the company announced Thursday.

  • FDA outlines efforts to reduce orphan drug designation backlog

    SILVER SPRING, Md. — The Food and Drug Administration is committing to eliminate its orphan drug designation request backlog within 90 days and respond to all orphan drug requests within 90 days of receipt. The agency on Thursday outlined its Orphan Drug Modernization plan, which it said is part of a larger effort called the Medical Innovation Development plan modernize and make efficient the FDA’s regulatory tools and policies.

  • Blink Health commits $10M to give patients year's supply of common diabetes meds

    NEW YORK —Blink Health has announced an effort to bring $10 million worth of free Type 2 diabetes medications to patients using the prescription drug savings platform.

    Patients with diabetes who create an account on the Blink Health website or mobile app will be able to receive a year’s supply of metformin, glipizide and pioglitazone for free. The progam also will cover existing Blink Health users who take these medications, the company said.

X
This ad will auto-close in 10 seconds